title: Report of the Association of British Pharmaceutical Industries Collaborative Study Group. Collaborative study to evaluate the inter/intra laboratory reproducibility and phenotypic stability of Salmonella typhimurium TA97a and TA102.
abstract: A collaborative trial was carried out to determine the intra/interlaboratory variability of Salmonella typhimurium strains TA102 and TA97a with regard to spontaneous revertant frequency and in response to four model mutagens (cumene hydroperoxide and bleomycin for strain TA102, and 4-nitrophenylenediamine and 4-aminoantipyrine for strain TA97a). A secondary objective of the trial was to monitor the stability of the strains after storage for up to 8 months and identify any technical problems associated with their use. Thirteen different laboratories participated in the trial, all receiving identical stock cultures of the bacterial strains and samples from the same batch of mutagenic compound. A standard protocol was followed and two independent experiments were carried out within 1 month of receipt of the strains/compounds (phase I), and again after a period of 6-8 months (phase II). Comparative studies with the standard strain TA100 after treatment with 4-nitrophenylenediamine were carried out as part of phase II. Overall, both strains gave acceptably consistent results in different laboratories and are considered useful for screening purposes when used under standardized conditions. One major source of interlaboratory variability identified for TA102 appears to be the sensitivity of different types of automatic colony counter for detecting the micro-colony revertants that this strain produces.
authors.affiliation: Genetic and Reproductive Toxicology Department, Glaxo Group Research Ltd, Ware, Hertfordshire, UK.
authors.forename: P
authors.initials: P
authors.lastname: Wilcox
authors.forename: D J
authors.initials: DJ
authors.lastname: Wedd
authors.forename: D
authors.initials: D
authors.lastname: Gatehouse
mesh_terms: D000675:Ampyrone / Q000494:pharmacology; D001555:Benzene Derivatives / Q000494:pharmacology; D001761:Bleomycin / Q000494:pharmacology; D004345:Drug Industry / Q000592:standards; D007753:Laboratories / Q000592:standards*; D009152:Mutagenicity Tests / Q000592:standards*; D009153:Mutagens / Q000494:pharmacology*; D010641:Phenotype; D010655:Phenylenediamines / Q000494:pharmacology; D012486:Salmonella typhimurium / Q000187:drug effects / Q000235:genetics*; D006113:United Kingdom
chemical_list: D001555:Benzene Derivatives; D009153:Mutagens; D010655:Phenylenediamines; D000675:Ampyrone; D001761:Bleomycin; C012277:1,2-diamino-4-nitrobenzene; C007164:cumene hydroperoxide